Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
ADAG similar filings
- 7 Jul 21 Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
- 19 May 21 Adagene Presents Clinical Data from NEObodyTM Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
- 13 Apr 21 Adagene Presents Preclinical Data from Lead SAFEbodyTM Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021
- 31 Mar 21 Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
- 29 Mar 21 Adagene Announces Clinical Advancement for ADG116
- 16 Mar 21 Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
Filing view
External links